Viridian Therapeutics, Inc. (VRDN): R&D Expense
$338.93M
Year ended 2025-12-31
$324.68M
Trailing 12 months to 2026-06-30
+49.8%
3-year compound annual growth
+64.3%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $338.93M | +42.3% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $238.25M | +49.1% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $159.76M | +58.3% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $100.89M | +77.4% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $56.89M | +101.0% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $28.30M | -18.7% | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | $34.79M | +14.4% | 2021-03-26, From 2019-01-01 |
| 2018-12-31 | $30.42M | +55.0% | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | $19.62M | +43.3% | 2019-03-14, From 2017-01-01 |
| 2016-12-31 | $13.69M | n/m | 2018-03-15, From 2016-01-01 |
| 2015-12-31 | $1.00M | +188.8% | 2017-03-24, From 2015-01-01 |
| 2014-12-31 | $347.0K | n/c | 2016-03-21, From 2014-01-01 |
| 2013-12-31 | $225.0K | n/a | 2015-03-27, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $338.93M | +42.3% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $64.81M | +15.9% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $0 | -100.0% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $240.28M | +38.9% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $251.07M | +47.7% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $186.83M | +11.7% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $38.47M | -60.2% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $68.73M | -17.6% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $106.74M | -18.8% |
Compare VRDN, ASMB, RMTI, BCYC side by side · Screen every company in Pharmaceutical Preparations ↗